CHRS
Price
$2.18
Change
+$0.11 (+5.31%)
Updated
Apr 22, 6:59 PM EST
16 days until earnings call
XNCR
Price
$18.21
Change
-$0.17 (-0.92%)
Updated
Apr 22, 6:59 PM EST
17 days until earnings call
Ad is loading...

Compare trend and price CHRS vs XNCR

Header iconCHRS vs XNCR Comparison
Open Charts CHRS vs XNCRBanner chart's image
Coherus BioSciences
Price$2.18
Change+$0.11 (+5.31%)
Volume$910.11K
CapitalizationN/A
Xencor
Price$18.21
Change-$0.17 (-0.92%)
Volume$288.51K
CapitalizationN/A
View a ticker or compare two or three
CHRS vs XNCR Comparison Chart

Loading...

CHRSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
XNCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CHRS vs. XNCR commentary
Apr 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and XNCR is a Hold.

COMPARISON
Comparison
Apr 23, 2024
Stock price -- (CHRS: $2.07 vs. XNCR: $18.38)
Brand notoriety: CHRS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 117% vs. XNCR: 114%
Market capitalization -- CHRS: $234.94M vs. XNCR: $1.12B
CHRS [@Biotechnology] is valued at $234.94M. XNCR’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $551.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 6 bearish.
  • XNCR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -7.17% price change this week, while XNCR (@Biotechnology) price change was -10.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.88%. For the same industry, the average monthly price growth was -4.06%, and the average quarterly price growth was +1246.46%.

Reported Earning Dates

CHRS is expected to report earnings on Aug 01, 2024.

XNCR is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Biotechnology (-2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CHRS with price predictions.
OPEN
A.I.dvisor published
a Summary for XNCR with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
XNCR($1.12B) has a higher market cap than CHRS($247M). XNCR YTD gains are higher at: -13.424 vs. CHRS (-34.535).
CHRSXNCRCHRS / XNCR
Capitalization247M1.12B22%
EBITDAN/AN/A-
Gain YTD-34.535-13.424257%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CHRS vs XNCR: Fundamental Ratings
CHRS
XNCR
OUTLOOK RATING
1..100
7450
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
8964
P/E GROWTH RATING
1..100
566
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (81) in the Biotechnology industry is in the same range as CHRS (90). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's SMR Rating (94) in the Biotechnology industry is in the same range as CHRS (100). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's Price Growth Rating (64) in the Biotechnology industry is in the same range as CHRS (89). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's P/E Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for CHRS (56). This means that XNCR’s stock grew somewhat faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 4 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 4 days ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 4 days ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
74%
View a ticker or compare two or three
Ad is loading...
CHRSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
XNCRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DEMRX20.680.33
+1.62%
Delaware Emerging Markets R
DTCYX17.550.18
+1.04%
BNY Mellon Sust US Equity Y
SFAAX38.330.22
+0.58%
Allspring Index Asset Allocation A
PRCHX25.770.09
+0.35%
T. Rowe Price Cap Apprec And Inc I
HSZAX5.51-0.01
-0.18%
NexPoint Climate Tech A

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ENTA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ENTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+5.31%
ENTA - CHRS
40%
Loosely correlated
+0.90%
AURA - CHRS
40%
Loosely correlated
-1.39%
ARRY - CHRS
39%
Loosely correlated
+3.73%
VERA - CHRS
38%
Loosely correlated
+2.97%
AXON - CHRS
38%
Loosely correlated
+0.07%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-3.01%
BEAM - XNCR
54%
Loosely correlated
-1.69%
PRME - XNCR
53%
Loosely correlated
-1.74%
VCYT - XNCR
52%
Loosely correlated
+1.30%
DNLI - XNCR
52%
Loosely correlated
-3.61%
NTLA - XNCR
51%
Loosely correlated
+1.17%
More